Prilenia Neurotherapeutics Ltd.

The University of Texas System

Agency for Science, Technology and Research

National University of Singapore

Teva Pharmaceutical Industries Limited

Hadasit Medical Research Services and Development Ltd.

Michael Hayden

Michal Geva

Beth E Borowsky

Merav Bassan

Eli Eyal

Ralph Laufer

Ilya Bezprozvanny

Aric Orbach

Juha-Matti Savola

Spyridon Papapetropoulos

Igor D Grachev

Yaron Ilan

David Ladkani

Amir Tchelet

Mark Forrest Gordon

Liat Hayardeny

Angela Cenci Nilsson

Einat Amit-Romach

Iris Grossman

Colin James Douglas Ross

Doina Cosma Roman

Mahmoud Abdulhossein Pouladi

Neta Zach

Elena Berelovich

Ana Cristina Carvalho Rego

The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.

Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism

The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

Use of pridopidine for treating rett syndrome

The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

Pridopidine for treating drug induced dyskinesias

The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

Use of pridopidine for treating dystonias

This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Method of treating amyotrophic lateral sclerosis with pridopidine

The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

Use of pridopidine for the treatment of fragile X syndrome

This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

Use of pridopidine for treating functional decline

The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:

Growing community of inventors

Herzliya, Israel

Michael Hayden